Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 1 357.6 INR -1.25% Market Closed
Market Cap: 243.2B INR
Have any thoughts about
Natco Pharma Ltd?
Write Note

Intrinsic Value

The intrinsic value of one NATCOPHARM stock under the Base Case scenario is 681.5 INR. Compared to the current market price of 1 357.6 INR, Natco Pharma Ltd is Overvalued by 50%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NATCOPHARM Intrinsic Value
681.5 INR
Overvaluation 50%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Natco Pharma Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NATCOPHARM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NATCOPHARM?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Natco Pharma Ltd

Provide an overview of the primary business activities
of Natco Pharma Ltd.

What unique competitive advantages
does Natco Pharma Ltd hold over its rivals?

What risks and challenges
does Natco Pharma Ltd face in the near future?

Has there been any significant insider trading activity
in Natco Pharma Ltd recently?

Summarize the latest earnings call
of Natco Pharma Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Natco Pharma Ltd.

Provide P/S
for Natco Pharma Ltd.

Provide P/E
for Natco Pharma Ltd.

Provide P/OCF
for Natco Pharma Ltd.

Provide P/FCFE
for Natco Pharma Ltd.

Provide P/B
for Natco Pharma Ltd.

Provide EV/S
for Natco Pharma Ltd.

Provide EV/GP
for Natco Pharma Ltd.

Provide EV/EBITDA
for Natco Pharma Ltd.

Provide EV/EBIT
for Natco Pharma Ltd.

Provide EV/OCF
for Natco Pharma Ltd.

Provide EV/FCFF
for Natco Pharma Ltd.

Provide EV/IC
for Natco Pharma Ltd.

Show me price targets
for Natco Pharma Ltd made by professional analysts.

What are the Revenue projections
for Natco Pharma Ltd?

How accurate were the past Revenue estimates
for Natco Pharma Ltd?

What are the Net Income projections
for Natco Pharma Ltd?

How accurate were the past Net Income estimates
for Natco Pharma Ltd?

What are the EPS projections
for Natco Pharma Ltd?

How accurate were the past EPS estimates
for Natco Pharma Ltd?

What are the EBIT projections
for Natco Pharma Ltd?

How accurate were the past EBIT estimates
for Natco Pharma Ltd?

Compare the revenue forecasts
for Natco Pharma Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Natco Pharma Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Natco Pharma Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Natco Pharma Ltd compared to its peers.

Compare the P/E ratios
of Natco Pharma Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Natco Pharma Ltd with its peers.

Analyze the financial leverage
of Natco Pharma Ltd compared to its main competitors.

Show all profitability ratios
for Natco Pharma Ltd.

Provide ROE
for Natco Pharma Ltd.

Provide ROA
for Natco Pharma Ltd.

Provide ROIC
for Natco Pharma Ltd.

Provide ROCE
for Natco Pharma Ltd.

Provide Gross Margin
for Natco Pharma Ltd.

Provide Operating Margin
for Natco Pharma Ltd.

Provide Net Margin
for Natco Pharma Ltd.

Provide FCF Margin
for Natco Pharma Ltd.

Show all solvency ratios
for Natco Pharma Ltd.

Provide D/E Ratio
for Natco Pharma Ltd.

Provide D/A Ratio
for Natco Pharma Ltd.

Provide Interest Coverage Ratio
for Natco Pharma Ltd.

Provide Altman Z-Score Ratio
for Natco Pharma Ltd.

Provide Quick Ratio
for Natco Pharma Ltd.

Provide Current Ratio
for Natco Pharma Ltd.

Provide Cash Ratio
for Natco Pharma Ltd.

What is the historical Revenue growth
over the last 5 years for Natco Pharma Ltd?

What is the historical Net Income growth
over the last 5 years for Natco Pharma Ltd?

What is the current Free Cash Flow
of Natco Pharma Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Natco Pharma Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Natco Pharma Ltd

Current Assets 40.2B
Cash & Short-Term Investments 18.5B
Receivables 12B
Other Current Assets 9.8B
Non-Current Assets 28.8B
Long-Term Investments 1.4B
PP&E 24.4B
Intangibles 1.9B
Other Non-Current Assets 1.1B
Current Liabilities 9.7B
Accounts Payable 2.4B
Short-Term Debt 3.6B
Other Current Liabilities 3.7B
Non-Current Liabilities 804m
Long-Term Debt 53m
Other Non-Current Liabilities 751m
Efficiency

Earnings Waterfall
Natco Pharma Ltd

Revenue
42.2B INR
Cost of Revenue
-7B INR
Gross Profit
35.2B INR
Operating Expenses
-16.8B INR
Operating Income
18.4B INR
Other Expenses
-2B INR
Net Income
16.4B INR

Free Cash Flow Analysis
Natco Pharma Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

NATCO Pharma achieved consolidated revenue of INR 1,434.9 crores for Q2 FY '25, marking a 35.3% year-over-year growth. The net profit climbed 82% to INR 676.5 million, driven by strong export formulations and a stable domestic market. The company expects a 20% revenue growth for the coming year. Additionally, they declared an interim dividend of INR 1.5 per share. The market share for Revlimid is projected to capture one-third of the market by January, without anticipated challenges in this fiscal year.

What is Earnings Call?
Fundamental Scores

NATCOPHARM Profitability Score
Profitability Due Diligence

Natco Pharma Ltd's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROE is Increasing
ROIC is Increasing
70/100
Profitability
Score

Natco Pharma Ltd's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

NATCOPHARM Solvency Score
Solvency Due Diligence

Natco Pharma Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Natco Pharma Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NATCOPHARM Price Targets Summary
Natco Pharma Ltd

Wall Street analysts forecast NATCOPHARM stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NATCOPHARM is 1 284.59 INR with a low forecast of 696.9 INR and a high forecast of 1 758.75 INR.

Lowest
Price Target
696.9 INR
49% Downside
Average
Price Target
1 284.59 INR
5% Downside
Highest
Price Target
1 758.75 INR
30% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NATCOPHARM?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for NATCOPHARM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

NATCOPHARM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Natco Pharma Ltd Logo
Natco Pharma Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

243B INR

Dividend Yield

0.41%

Description

NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the development, manufacture and commercialization of complex pharmaceuticals catering to niche therapeutic areas. The firm deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The firm operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

Contact

TELANGANA
Hyderabad
Natco House, Road No 2, Banjara Hills
+914023547532
www.natcopharma.co.in

IPO

1995-01-23

Employees

5 046

Officers

MD & Chairman
Mr. Venkaiah Chowdary Nannapaneni M. Pharm, MS.
CEO & Vice Chairman
Mr. Rajeev Nannapaneni
Chief Financial Officer
Mr. S. V. V. N. Appa Rao
President of Technical Affairs & Whole Time Director
Dr. Donthineni Linga Rao M.D.
Company Secretary & Compliance Officer
Mr. Chekuri Venkat Ramesh C.S.
Executive VP of Corporate Engineering Services & Whole Time Director
Mr. Potluri Sivaramakrishna Prasad
Show More
Executive VP of Technical Operations & Director
Dr. Pavan Ganapati Bhat
VP & Head of Operations
Nadella Malleswara Rao
Executive Vice President of Corporate Affairs, Legal, Secretarial & Estate Management
N. Sadasiva Rao
Vice President of Marketing & Sales - Domestic
James Rajakumar
Show Less

See Also

Discover More
What is the Intrinsic Value of one NATCOPHARM stock?

The intrinsic value of one NATCOPHARM stock under the Base Case scenario is 681.5 INR.

Is NATCOPHARM stock undervalued or overvalued?

Compared to the current market price of 1 357.6 INR, Natco Pharma Ltd is Overvalued by 50%.

Back to Top